Management of Low Renin Levels Despite ACE Inhibitor Treatment

Patient Selection and Initial Assessment

The American College of Cardiology recommends verifying low renin levels despite adequate ACE inhibitor dosing and checking baseline renal function, with creatinine levels <2.5 mg/dL in men and <2.0 mg/dL in women, before initiating spironolactone therapy, particularly in patients with LVEF ≤35% and NYHA class II-IV symptoms, as assessed by the European Society of Cardiology 1, 2

The initial dose of spironolactone should be 12.5-25 mg once daily, with monitoring of renal function and serum electrolytes at 1 and 4 weeks after starting treatment, and dose up-titration can be considered after 4-8 weeks if well-tolerated, with a target dose of 50 mg daily, as recommended by the European Society of Cardiology 2
Regular monitoring of renal function and electrolytes is necessary, with checks at 1, 2, 3, and 6 months after achieving maintenance dose, then every 6 months, to minimize the risk of hyperkalemia and worsening renal function 2

If potassium levels rise to >5.5 mmol/L, the dose should be halved, and if potassium levels rise to ≥6.0 mmol/L, spironolactone should be stopped immediately, as per the European Society of Cardiology guidelines 2
Parameters to monitor include serum potassium (target <5.0 mEq/L), renal function (creatinine, eGFR), clinical signs of fluid status, and symptoms of heart failure, with checking serum potassium and renal function within 2-3 days and rechecking at 7 days after dose reduction, with monthly monitoring for the first 3 months and every 3 months thereafter if stable 3

Eplerenone can be used as an alternative to spironolactone, particularly in men with breast discomfort or enlargement, with a starting dose of 25 mg once daily and a target dose of 50 mg once daily, as recommended by the European Society of Cardiology 2
Triple therapy with ACE inhibitor, ARB, and aldosterone antagonist should be avoided due to increased risk of hyperkalemia and renal dysfunction, as recommended by the American College of Cardiology and the American Heart Association 4, 3
Concomitant use of ACE inhibitors or ARBs increases the risk of hyperkalemia, and NSAIDs should be avoided, with advanced age being a risk factor for hyperkalemia, according to the American College of Cardiology 3, 5

Patients should be counseled to avoid high-potassium foods and supplements, and advised to temporarily discontinue spironolactone during episodes of diarrhea or dehydration, with consideration of further reducing the dose to alternate-day dosing if potassium rises to >5.5 mEq/L, and temporary discontinuation if creatinine rises to >2.5 mg/dL in men or >2.0 mg/dL in women, or eGFR falls below 30 mL/min/1.73 m² 3, 2
The American Heart Association advises against discontinuing spironolactone completely unless absolutely necessary, as it provides mortality benefit in heart failure 3